PL2512236T3 - Ulepszony sposób podawania beta-hydroksy-beta-metylomaślanu (hmb) - Google Patents

Ulepszony sposób podawania beta-hydroksy-beta-metylomaślanu (hmb)

Info

Publication number
PL2512236T3
PL2512236T3 PL10838355T PL10838355T PL2512236T3 PL 2512236 T3 PL2512236 T3 PL 2512236T3 PL 10838355 T PL10838355 T PL 10838355T PL 10838355 T PL10838355 T PL 10838355T PL 2512236 T3 PL2512236 T3 PL 2512236T3
Authority
PL
Poland
Prior art keywords
beta
hmb
methylbutyrate
hydroxy
improved method
Prior art date
Application number
PL10838355T
Other languages
English (en)
Inventor
John Rathmacher
John Fuller
Shawn Baier
Steve Nissen
Naji Abumrad
Original Assignee
Metabolic Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Technologies, Inc. filed Critical Metabolic Technologies, Inc.
Publication of PL2512236T3 publication Critical patent/PL2512236T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10838355T 2009-12-18 2010-12-20 Ulepszony sposób podawania beta-hydroksy-beta-metylomaślanu (hmb) PL2512236T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28785709P 2009-12-18 2009-12-18

Publications (1)

Publication Number Publication Date
PL2512236T3 true PL2512236T3 (pl) 2017-06-30

Family

ID=44167737

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10838355T PL2512236T3 (pl) 2009-12-18 2010-12-20 Ulepszony sposób podawania beta-hydroksy-beta-metylomaślanu (hmb)

Country Status (11)

Country Link
US (1) US20120053240A1 (pl)
EP (1) EP2512236B1 (pl)
JP (2) JP6077857B2 (pl)
CN (1) CN102762097B (pl)
CA (1) CA2784836C (pl)
DK (1) DK2512236T3 (pl)
ES (1) ES2608483T3 (pl)
HU (1) HUE032486T2 (pl)
PL (1) PL2512236T3 (pl)
PT (1) PT2512236T (pl)
WO (1) WO2011075741A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2841748C (en) * 2011-07-15 2021-06-15 Nusirt Sciences, Inc. Compositions and methods for modulating metabolic pathways
DK3733171T3 (da) * 2012-09-10 2024-01-29 Metabolic Tech Llc Sammensætninger omfattende hmb og atp samt anvendelse deraf
US20140272000A1 (en) * 2013-03-14 2014-09-18 Metabolic Technologies, Inc. Liquids and Foodstuffs Containing beta-hydroxy-beta-methylbutyrate (HMB) in the Free Acid Form and Methods of Manufacturing or Producing the Same
EP2993994A4 (en) * 2013-03-14 2016-11-23 Metabolic Technologies Inc LIQUIDS AND FOODS WITH BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) IN A FREE ACID FORM
EP2968236A2 (en) 2013-03-14 2016-01-20 Abbott Laboratories Treatment of insulin resistance associated with prolonged physical inactivity
CA2903561C (en) * 2013-03-15 2017-09-26 Abbott Laboratories Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, casein phosphopeptide, and protein
US20150057350A1 (en) * 2013-08-23 2015-02-26 Abbott Laboratories Fibrosis biomarkers and methods of using same
EP3082778B1 (en) * 2013-12-18 2019-04-03 Capsugel Belgium NV Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid
WO2015105981A2 (en) * 2014-01-09 2015-07-16 Abbott Laboratories Conditional essentiality of hmb
EP3099411A4 (en) 2014-01-28 2017-09-20 The Methodist Hospital Single-cell pipette assembly comprising single-cell pipette handle and single-cell pipette tip
JP6309287B2 (ja) * 2014-01-29 2018-04-11 協和発酵バイオ株式会社 3−ヒドロキシ−3−メチル酪酸カルシウム含有飲料
JP6480964B2 (ja) * 2014-03-14 2019-03-13 メタボリック・テクノロジーズ,インコーポレーテッド 遊離酸形のβ−ヒドロキシ−β−メチル酪酸(HMB)を含有する液体及び食品ならびにその製造法
US20160184248A1 (en) * 2014-12-15 2016-06-30 University Of Central Florida Research Foundation Inc. Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response
US20160346238A1 (en) 2015-06-01 2016-12-01 Metabolic Technologies, Inc. Compositions and Methods of Use of -hydroxy--methylbutyrate (HMB) for Decreasing Fat Mass
EP3349745B1 (en) 2015-09-16 2023-12-13 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for enhancing recovery from soft tissue trauma
US12208073B2 (en) 2015-09-16 2025-01-28 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
HUE055046T2 (hu) 2015-11-10 2021-10-28 Metabolic Tech Inc A hidroxi-metilbutirát (HMB) takarmány-adalékanyagként való felhasználására szolgáló készítmények és módszerek
MX386153B (es) * 2016-01-13 2025-03-18 Metabolic Tech Inc COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA ESTABILIDAD DE ARTICULACIÓN.
CN109641135A (zh) 2016-01-21 2019-04-16 代谢科技有限公司 β-羟基-β-甲基丁酸(HMB)用于调节自噬和噬脂的组合物和方法
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
WO2017205673A1 (en) 2016-05-25 2017-11-30 TSI Group Ltd. Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules
US10588877B2 (en) 2016-07-21 2020-03-17 Savind, Inc. Compositions comprising β-hydroxybutyric acid and salt, and methods of using the same
EP3528801B1 (en) 2016-10-21 2024-07-17 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) and probiotics
US12370159B2 (en) * 2016-10-21 2025-07-29 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) and probiotics
JP7022420B2 (ja) * 2017-06-30 2022-02-18 株式会社東洋新薬 経口組成物
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
CN112105352A (zh) * 2018-01-05 2020-12-18 得克萨斯理工大学研究商业化办公室 与间歇性禁食相关的β-羟基-β-甲基丁酸(HMB)组合物和使用方法
US11419836B2 (en) 2019-02-13 2022-08-23 Axcess Global Sciences, Llc Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions
US10888576B2 (en) 2018-10-08 2021-01-12 Metabolic Technologies, Inc. Composition of HMB and ATP and methods of use
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US12186297B2 (en) * 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857552A (en) * 1988-06-08 1989-08-15 E. I. Du Pont De Nemours And Co. Stable pharmaceutical composition
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US4992470A (en) * 1990-02-08 1991-02-12 Iowa State University Research Foundation, Inc. Method of enhancing immune response of mammals
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US6103764A (en) * 1997-11-07 2000-08-15 Iowa State University Research Foundation, Inc. Method for increasing the aerobic capacity of muscle
US6031000A (en) * 1998-06-23 2000-02-29 Iowa State University Research Foundation, Inc. Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
US20010008641A1 (en) * 1998-11-25 2001-07-19 R. Douglas Krotzer Nutritionally active composition for bodybuilding
AU2002335689B2 (en) * 2001-08-31 2008-08-07 Rutgers, The State University Of New Jersey Methods for treating disorders using plant extracts
DE10215007A1 (de) * 2002-04-05 2003-10-16 Degussa Bioactives Deutschland Verwendung von Kreatinpyruvat zur Steigerung der Ausdauer bei hochintensiven körperlichen Intervallbelastungen
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
EP1750527A1 (en) * 2004-03-11 2007-02-14 Wiley Organics, Inc. Compositions and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
WO2007056176A2 (en) * 2005-11-03 2007-05-18 Southwest Immunology, Inc. Compositions for preventing and reducing delayed onset muscle soreness
DK2381784T3 (en) * 2008-12-09 2018-10-22 Metabolic Tech Inc Nutritional intervention to improve muscle function and strength
JP2009155336A (ja) * 2009-03-31 2009-07-16 Tsujido Chemical Corp 治療剤

Also Published As

Publication number Publication date
ES2608483T3 (es) 2017-04-11
WO2011075741A1 (en) 2011-06-23
EP2512236A4 (en) 2013-06-19
CA2784836A1 (en) 2011-06-23
PT2512236T (pt) 2016-12-29
CN102762097B (zh) 2015-06-17
CA2784836C (en) 2019-08-20
CN102762097A (zh) 2012-10-31
JP6077857B2 (ja) 2017-02-08
EP2512236B1 (en) 2016-10-19
JP2013515009A (ja) 2013-05-02
US20120053240A1 (en) 2012-03-01
HUE032486T2 (en) 2018-05-02
EP2512236A1 (en) 2012-10-24
JP2016026181A (ja) 2016-02-12
DK2512236T3 (en) 2017-01-16

Similar Documents

Publication Publication Date Title
PL2512236T3 (pl) Ulepszony sposób podawania beta-hydroksy-beta-metylomaślanu (hmb)
AP3155A (en) Methods of administering pirfenidone therapy
IL214919A0 (en) Method for therapeutic use
GB201018147D0 (en) Method of treatment
SI2427477T1 (sl) Postopek priprave ciklopeptidov
IL216951A0 (en) Method for treatment of diseases
GB201003920D0 (en) Method of treatment
IL213955A (en) Method for improved biological activity of pharmaceutical preparations
GB0908101D0 (en) Treatment of stress
GB201018149D0 (en) Method of treatment
EP2424539A4 (en) PROCESS FOR TREATING DEPRESSION
EP2404891A4 (en) PROCESS FOR THE PREPARATION OF ACYLBENZENES
EP2585103A4 (en) METHOD OF TREATMENT
GB201020015D0 (en) Method of treatment
AP2984A (en) An arteether injection for treatment of malaria
GB0909807D0 (en) Method of treatment
GB0921823D0 (en) Method of treatment
GB0904164D0 (en) Method of treatment
GB0920070D0 (en) Method of processing blood
GB201005071D0 (en) Method of treatment
GB201000318D0 (en) Method of treatment
GB201003917D0 (en) Method of treatment
GB201019936D0 (en) Therapeutic method
GB0915895D0 (en) Method of cleansing
AU2009903360A0 (en) Method of Treatment